MOS Fitness Team – Ashley
On May 17, 2022, despite the mass deaths and injuries reports among children in the U.S. following the CCP virus vaccine injections, the U.S. Food and Drug Administration (FDA) announced that it amended the emergency use authorization (EUA) for the Pfizer/BioNTech’s CCP virus vaccine, authorizing the use of a single booster dose of “Comirnaty” for administration to individuals 5 through 11 years of age.
As reported earlier, on Apr 26, Pfizer/BioNTech applied to the FDA for emergency use authorization (EUA) for a booster shot of the Pfizer/BioNTech CCP virus vaccine for children 5 through 11 years of age.
Under the terms of “FDA Evaluation of Safety,” the FDA claims “a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine in this age group was assessed, the most commonly reported side effects were pain, redness, and swelling at the injection site, as well as fatigue, headache, muscle or joint pain and chills and fever”, which does not match the records of the CDC’s Vaccine Adverse Event Reporting System (VAERS).
As of Apr 22, 2022, according to CDC’s VAERS data report, there have been 106 deaths and 48,033 adverse reactions following CCP virus vaccine injections among children, of which 12,548 were considered serious injuries resulting in hospitalization and permanent disability.
Considering that the CDC used to claim that estimated only as little as 1% of adverse reactions are reported to the system, the actual number of deaths and injuries caused by CCP virus vaccines could be 100 times the reported.
According to a media report, as early as Jan 3, 2022, the FDA has authorized a single booster dose of the Pfizer/BioNTech CCP virus vaccine for administration to individuals 12 through 15 years of age.
The FDA did not hold any meeting of its Vaccines and Related Biological Products Advisory Committee on its EUA action, claiming it would make relevant documents regarding the authorization available on its website.
Edited and posted by: Kayla J.